CA2814120C - Novel anti-cancer agents - Google Patents

Novel anti-cancer agents Download PDF

Info

Publication number
CA2814120C
CA2814120C CA2814120A CA2814120A CA2814120C CA 2814120 C CA2814120 C CA 2814120C CA 2814120 A CA2814120 A CA 2814120A CA 2814120 A CA2814120 A CA 2814120A CA 2814120 C CA2814120 C CA 2814120C
Authority
CA
Canada
Prior art keywords
4alkyl
group
independently selected
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2814120A
Other languages
English (en)
French (fr)
Other versions
CA2814120A1 (en
Inventor
Antony Wilks Burgess
Francesca Walker
Keith Geoffrey Watson
Helen Witchard
Guillaume Lessene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of CA2814120A1 publication Critical patent/CA2814120A1/en
Application granted granted Critical
Publication of CA2814120C publication Critical patent/CA2814120C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2814120A 2010-10-27 2011-10-27 Novel anti-cancer agents Active CA2814120C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40726510P 2010-10-27 2010-10-27
US61/407,265 2010-10-27
PCT/AU2011/001376 WO2012054978A1 (en) 2010-10-27 2011-10-27 Novel anti-cancer agents

Publications (2)

Publication Number Publication Date
CA2814120A1 CA2814120A1 (en) 2012-05-03
CA2814120C true CA2814120C (en) 2018-08-07

Family

ID=45992970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2814120A Active CA2814120C (en) 2010-10-27 2011-10-27 Novel anti-cancer agents

Country Status (12)

Country Link
US (3) US8835629B2 (enExample)
EP (1) EP2632916B1 (enExample)
JP (2) JP6184866B2 (enExample)
KR (1) KR101896924B1 (enExample)
CN (1) CN103476769B (enExample)
AU (1) AU2011320024B2 (enExample)
CA (1) CA2814120C (enExample)
ES (1) ES2621932T3 (enExample)
HU (1) HUE032522T2 (enExample)
NZ (1) NZ609186A (enExample)
PL (1) PL2632916T3 (enExample)
WO (1) WO2012054978A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6184866B2 (ja) * 2010-10-27 2017-08-23 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 新規抗がん剤
KR101853785B1 (ko) 2013-11-20 2018-05-02 주식회사 만도 3상모터 제어장치 및 그의 고토크 유지 방법
WO2016070241A1 (en) * 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
WO2018226923A1 (en) * 2017-06-08 2018-12-13 University Of South Alabama Antimicrobial compounds
MX2020007535A (es) 2018-01-17 2020-12-07 Aurigene Discovery Tech Ltd Compuestos de alquinileno sustituidos como agentes anticancerigenos.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1035771A (enExample)
US2742466A (en) 1956-04-17 Chx n nhx c c
US3145203A (en) 1961-11-30 1964-08-18 Geigy Chem Corp Hydrazones of 5-nitro-2-furaldehyde
JPS5277163A (en) 1975-12-24 1977-06-29 Asahi Chem Ind Co Ltd Stabilized polyurethane composition
FR2524467A1 (fr) 1982-03-30 1983-10-07 Adir Polymethylene-imines disubstituees, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
JPS62192474A (ja) 1986-02-19 1987-08-24 Canon Inc 記録液
US4932998A (en) 1986-09-30 1990-06-12 Idemitsu Kosan Company Limited Triazine derivatives, and herbicides comprising the same as the effective ingredient
US4844731A (en) 1986-12-27 1989-07-04 Idemitsu Company Co., Ltd. Triazine derivatives
US5187045A (en) 1988-09-07 1993-02-16 Minnesota Mining And Manufacturing Company Halomethyl-1,3,5-triazines containing a sensitizer moiety
EP0411153B1 (en) 1989-02-20 1996-09-11 Idemitsu Kosan Company Limited Triazine derivative and herbicide containing the same as active ingredient
CA2123402A1 (en) 1991-11-12 1993-05-27 Jotham W. Coe Triazine derivatives for enhancing antitumor activity
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
US5574057A (en) * 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
FR2757057A1 (fr) 1996-12-17 1998-06-19 Oreal Compositions comprenant un derive de dibenzoylmethane, un derive de 1,3,5-triazine et un derive silicie a fonction benzalmalonate et utilisations
FR2757056B1 (fr) 1996-12-17 2003-03-14 Oreal Compositions comprenant un derive de dibenzoylmethane, un derive de 1,3,5-triazine et un compose amide et utilisations
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
US6262053B1 (en) 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
AU2002246855B2 (en) * 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
EP1441683A4 (en) 2001-10-12 2005-10-26 Univ New York TRISUBSTITUTED TRIAZIN COMPOUNDS AND METHOD FOR THE PREPARATION AND USE OF THE COMPOUNDS WITH ANTITUBULIN EFFECT
CN1697831A (zh) * 2002-09-23 2005-11-16 雷迪美国治疗公司 新三嗪化合物的制备方法和组合物
JP6184866B2 (ja) * 2010-10-27 2017-08-23 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 新規抗がん剤

Also Published As

Publication number Publication date
PL2632916T3 (pl) 2017-07-31
HUE032522T2 (en) 2017-09-28
EP2632916A1 (en) 2013-09-04
NZ609186A (en) 2015-08-28
JP2013540778A (ja) 2013-11-07
EP2632916A4 (en) 2014-04-23
US9221799B2 (en) 2015-12-29
US20150045365A1 (en) 2015-02-12
US20130261119A1 (en) 2013-10-03
AU2011320024B2 (en) 2014-10-30
JP2017137323A (ja) 2017-08-10
ES2621932T3 (es) 2017-07-05
CA2814120A1 (en) 2012-05-03
KR20130141554A (ko) 2013-12-26
US8835629B2 (en) 2014-09-16
AU2011320024A1 (en) 2013-05-02
WO2012054978A1 (en) 2012-05-03
EP2632916B1 (en) 2017-01-11
JP6184866B2 (ja) 2017-08-23
KR101896924B1 (ko) 2018-09-10
CN103476769A (zh) 2013-12-25
CN103476769B (zh) 2016-06-01
US20160145243A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
ES2799520T3 (es) Compuestos de pirazolo[3,4-d]pirimidina o sales de los mismos
CA2956628C (en) Pyridinylaminopyrimidine derivatives, preparation process and use thereof
Sączewski et al. Synthesis, structure and anticancer activity of novel 2, 4-diamino-1, 3, 5-triazine derivatives
ES2402791T3 (es) Forma cristalina de la sal diclorhidrato de ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
ES2906785T3 (es) Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones
KR20190114910A (ko) 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
ES2738573T3 (es) Sal de compuesto heterocíclico que contiene nitrógeno o cristal del mismo, composición farmacéutica e inhibidor de FLT3
US9221799B2 (en) Anti-cancer agents
AU2016292450A1 (en) Aniline pyrimidine derivatives and uses thereof
JP2023534492A (ja) ピリダジン誘導体遊離塩基の結晶形態、並びにその調製方法及びその使用
CN110267940A (zh) 四取代的烯烃化合物和它们的用途
KR20210039228A (ko) 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 피리미디나다이벤젠아사이클로헵타판 유도체
KR20130118731A (ko) 항증식성 질환 치료에 사용하기 위한 ｐｉ3ｋ 억제제로서 피페라지노트리아진
JP6927959B2 (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
AU2019208515A1 (en) Substituted alkynylene compounds as anticancer agents
CN118684666A (zh) Kif18a抑制剂及其用途
EP3192792A1 (en) Aminosulfonyl compound, preparation method therefor and use thereof
AU2014280992A1 (en) Novel Anti-Cancer Agents
JP7863272B2 (ja) フルオロアルコキシアルキレン－ジヒドロイミダゾ［５，１－ｄ］テトラジノン化合物および関連化合物ならびに医学的症状の治療におけるそれらの使用
CN111269215A (zh) 含氮杂环有机化合物及其制备方法和应用
JP7460177B2 (ja) エピジェネティックスを標的とした新規医薬
EP4506346A1 (en) Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
CN119546309A (zh) 包括kras g12c抑制剂和aurora a抑制剂的治疗方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161013

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251216

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260121

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260608

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713